Betaine Reverses Placental Hypoxia and Growth Restriction in Mouse Model of Depression

Placental Vascular Integrity and Maternal Mental Health

Perinatal depression remains a prevalent psychiatric challenge that may extend beyond maternal mood to influence intrauterine development. Fetal growth restriction, a condition where a fetus fails to reach its biological growth potential, is a significant driver of neonatal morbidity with long-term consequences that persist throughout the lifespan [1]. While the etiology of growth restriction is multifactorial, metabolic disturbances and oxidative stress, an imbalance between free radicals and antioxidants that can damage cellular structures, often compromise maternal-fetal homeostasis during the transition from late gestation to lactation [2]. Choline and its metabolite betaine are critical regulators of cellular function, serving as essential methyl donors that influence gene expression through the addition of methyl groups to DNA. Mendelian randomization studies, a method using genetic variants to determine if a risk factor causes a health outcome, have linked these metabolites to 27 distinct health outcomes, including metabolic and neurological conditions [3, 4]. Given that nutritional interventions like choline are currently being investigated to support central nervous system embryogenesis, the formation of the brain and spinal cord, a new study examines the potential for betaine to counteract placental vascular impairments linked to maternal stress [5].

Modeling Perinatal Stress and Vascular Signaling

Perinatal depression is a complex psychiatric disorder characterized by persistent low mood, difficulty adapting to gestational changes, helplessness, and social withdrawal. In severe clinical presentations, patients may experience suicidal or infanticidal thoughts, necessitating a deeper understanding of the biological pathways connecting maternal mental health to fetal outcomes. To investigate these physiological underpinnings, researchers utilized a mouse model to examine placental angioneurotrophic signaling, which involves the coordinated action of growth factors that support both vascular and neural development. Specifically, the study focused on vascular endothelial growth factor (VEGF), VEGF receptor-1 (VEGFR1), and brain-derived neurotrophic factor (BDNF). VEGF is a signaling protein that stimulates the formation of blood vessels, while BDNF is a protein that supports the survival of existing neurons and encourages the growth and differentiation of new neurons and synapses. The discovery cohort consisted of 40 pregnant C57BL/6 mice subjected to a rigorous stress protocol involving six weeks of pre-mating chronic unpredictable mild stress (CUMS), a method that uses varied environmental stressors to induce depressive-like behaviors, combined with social isolation. These stressors continued through pregnancy until gestational day 14. For comparison, the researchers maintained a control group of 10 non-stressed littermates. Following the stress protocol, the model dams were randomized into four distinct treatment arms. One group of 10 mice received a physiological saline vehicle (10 mL/kg/day), designated as the DD group. Two groups were treated with betaine: 10 mice received a low-dose of 50 mg/kg/day (DD+LB) and 10 mice received a high-dose of 200 mg/kg/day (DD+HB). A final group of 10 mice received escitalopram at 10 mg/kg/day (DD+ESC), a common selective serotonin reuptake inhibitor. Both the stress protocol and these pharmacological treatments were maintained until gestational day 17, providing a window to assess the impact of these interventions on placental health and fetal growth.

Hypoxia and Impaired Angiogenesis in the Depressed Model

The researchers confirmed the validity of the perinatal depression model by observing that chronic unpredictable mild stress combined with social isolation evoked robust depression and anxiety like behaviors in the mice. This psychological stress manifested physically as attenuated maternal weight gain compared to the non-stressed control group. On gestational day 18, the team recorded fetal and placental weights to calculate placental efficiency, a measure of the placenta's ability to support fetal growth relative to its own mass. The results demonstrated that perinatal depression resulted in significant fetal growth restriction and decreased placental efficiency, indicating that the maternal stress response directly compromised the intrauterine environment and restricted the physical development of the offspring. To understand the biological drivers of these growth deficits, the researchers investigated whether placental hypoxia, a state of oxygen deficiency in the tissue, precipitates impaired angiogenesis, the formation of new blood vessels, and fetal growth restrictions. They quantified placental levels of VEGF, VEGFR1, BDNF, and hypoxia-inducible factor-1α (HIF-1α) using reverse transcription quantitative polymerase chain reaction and western blot. The findings revealed marked reductions in placental BDNF and VEGF in the stressed group. These alterations coincided with elevated levels of HIF-1α, a protein that serves as a primary molecular marker for placental hypoxia, suggesting that the stressed maternal state creates a low-oxygen environment that hinders essential growth signaling. The structural consequences of these molecular changes were evaluated through detailed histological analysis of the placental tissue. The researchers assessed microvascular density (MVD), which measures the concentration of small blood vessels in a specific tissue area, and vascular architecture using CD34 immunohistochemistry, a staining technique that identifies vascular endothelial cells, and hematoxylin eosin staining. This analysis confirmed that the reduction in growth factors and the presence of hypoxia were associated with impaired vascular development, providing a clear mechanism for the observed fetal growth restriction.

High-Dose Betaine as a Metabolic Rescue Mechanism

The researchers evaluated the therapeutic potential of betaine in restoring placental function and fetal growth by comparing different treatment regimens in the stressed mouse model. While low-dose betaine (50 mg/kg/day) and escitalopram (10 mg/kg/day) were tested, the most significant physiological recovery was observed in the group receiving high-dose betaine at 200 mg/kg/day. This high-dose intervention successfully reversed the deficits caused by chronic unpredictable mild stress, restoring both fetal weight and placental efficiency to levels comparable to the non-stressed control group. By gestational day 18, the administration of 200 mg/kg/day of betaine had effectively mitigated the growth restrictions that characterized the untreated perinatal depression model, suggesting that betaine may act as a metabolic stabilizer in the presence of maternal psychological stress. At the molecular level, the study found that high-dose betaine upregulated the expression of placental BDNF and VEGF. These signaling molecules are critical for maintaining the integrity of the maternal-fetal interface; their restoration suggests that betaine helps bypass the inhibitory effects of hypoxia-inducible factor-1α. Histological assessments further confirmed these molecular improvements. In the high-dose betaine group, the researchers observed an increase in microvascular density and improved vascular perfusion, which refers to the passage of blood through the placental circulatory system. By enhancing the physical architecture of the placental vasculature, high-dose betaine ensured more robust nutrient and oxygen delivery to the developing fetus. These findings highlight betaine as a potential low-risk intervention for preventing fetal complications associated with perinatal depression, offering a metabolic strategy to protect intrauterine development in high-risk pregnancies.

References

1. Yao M, Yang Z, Rong X, et al. The Exploration of Fetal Growth Restriction Based on Metabolomics: A Systematic Review. Metabolites. 2022. doi:10.3390/metabo12090860

2. Khan MZ, Liu S, Ma Y, et al. Overview of the effect of rumen-protected limiting amino acids (methionine and lysine) and choline on the immunity, antioxidative, and inflammatory status of periparturient ruminants. Frontiers in Immunology. 2023. doi:10.3389/fimmu.2022.1042895

3. Louck LE, Cara KC, Klatt KC, Wallace TC, Chung M. The Relationship of Circulating Choline and Choline-Related Metabolite Levels with Health Outcomes: A Scoping Review of Genome-Wide Association Studies and Mendelian Randomization Studies. Advances in Nutrition. 2023. doi:10.1016/j.advnut.2023.100164

4. Maia C, Fung CW, Sánchez‐López E. Choline in immunity: a key regulator of immune cell activation and function. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1617077

5. Andreu-Férnández V, Maida NL, Marquina M, et al. Novel Interventions on Comorbidities in Patients with Fetal Alcohol Spectrum Disorder (FASD): An Integrative Review. Biomedicines. 2024. doi:10.3390/biomedicines12030496